BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor

  • Artif Organs. 1996 Aug;20(8):849-52. doi: 10.1111/j.1525-1594.1996.tb04557.x.
Y Wada  1 ,  A Yagihashi ,  K Terasawa ,  N Miyao ,  K Hirata ,  J Cicciarelli ,  Y Iwaki
Affiliations
  • 1. First Department of Surgery, Sapporo Medical University, School of Medicine, Japan.
PMID: 8853794 DOI: 10.1111/j.1525-1594.1996.tb04557.x
Abstract

We evaluated the efficacy of a new purine nucleoside Phosphorylase Inhibitor, BCX-34, as an immunosuppressive agent. BCX-34 showed a complete inhibitory effect on the proliferation of T-cells in an in vitro system, whereas no influence was observed in B-cell lines. In addition, it was revealed that this inhibitory effect was not due to the suppression of interleukin-2 production. Therefore, BCX-34 might be a potentially useful drug that can be used in combination, not competition, with cyclosporine A and FK506.

Products